Clinical Trials Logo

Advanced/Metastatic Solid Tumors clinical trials

View clinical trials related to Advanced/Metastatic Solid Tumors.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05394168 Active, not recruiting - Clinical trials for Advanced/Metastatic Solid Tumors

A Phase I Clinical Study of HLX53 in Advanced/Metastatic Solid Tumors

Start date: December 9, 2022
Phase: Phase 1
Study type: Interventional

This phase I, first-in-human, open-label clinical study will evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of HLX53 (an anti-TIGIT Fc fusion protein) in patients with advanced/metastatic solid tumors.

NCT ID: NCT04501276 Active, not recruiting - Clinical trials for Advanced/Metastatic Solid Tumors

A Phase 1b/2 Study of ADG116, ADG116 Combined With Anti-PD-1 Antibody or Anti-CD137 Antibody in Solid Tumors Patients

Start date: September 23, 2020
Phase: Phase 1
Study type: Interventional

This is a Phase 1, open-label, dose escalation study in patients with advanced/metastatic solid tumors. Study drug, ADG116, is an anti -CTLA-4 fully human monoclonal antibody that specifically binds to human CTLA-4. ADG106, a fully human ligand-blocking agonistic anti-CD137 IgG4 mAb, is expected to enhance the activity of activated T cells. The enhanced antitumor efficacy results observed from the preclinical studies of ADG116 in combination with ADG106 or anti-PD-1 provided further support to explore such combinations in clinical settings for better patient responses.

NCT ID: NCT04182516 Active, not recruiting - Clinical trials for Advanced/Metastatic Solid Tumors

Study of NMS-03305293 in Pts With Selected Advanced/Metastatic Solid Tumors

Start date: November 25, 2019
Phase: Phase 1
Study type: Interventional

Phase I, first-in-human, open-label, multicenter, dose-escalation and dose expansion study with the aim of exploring safety, tolerability and preliminary antitumor activity of NMS-03305293 (a PARP inhibitor) as single agent in adult patients with selected advanced/metastatic, relapsed/refractory solid tumors who have exhausted standard treatment options or for whom standard therapy is considered unsuitable.